[1]
Consensus development conference diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94(6): 646-50.
[2]
Cooper C. Epidemiology of osteoporosis. Osteoporos Int 1999; 9(Suppl. 2): S2-8.
[3]
Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008; 22(5): 671-85.
[4]
Bliuc D, Nguyen N, Milch V, Nguyen T, Eisman J, Center J. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301(5): 513-21.
[5]
Svartberg J, Midtby M, Bønaa K, Sundsfjord J, Joakimsen R, Jorde R. The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromsø Study. Eur J Endocrinol 2003; 149(2): 145-52.
[6]
Morley J, Perry H, Kaiser F, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41(2): 149-52.
[7]
Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75(4): 1092-8.
[8]
Devogelaer JP, De Cooman S, Nagant de Deuxchaisnes C. Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study. Maturitas 1992; 15(1): 17-23.
[9]
Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81(12): 4358-65.
[10]
Snyder P, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84(6): 1966-72.
[11]
Kenny A, Prestwood K, Gruman C, Marcello K, Raisz L. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56(5): M266-72.
[12]
Amory J, Watts N, Easley K, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89(2): 503-10.
[13]
Tracz MJ, Sideras K, Bolona ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006; 91(6): 2011-6.
[14]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research
ed) 1997; 315(7109): 629-34.
[15]
Kenny AM, Kleppinger A, Annis K, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010; 58(6): 1134-43.
[16]
Snyder P, Kopperdahl D, Stephens-Shields A, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: A controlled clinical trial. JAMA Intern Med 2017; 177(4): 471-9.
[17]
Adams J. Quantitative computed tomography. Eur J Radiol 2009; 71(3): 415-24.
[18]
Hlaing TT, Compston JE. Biochemical markers of bone turnover - uses and limitations. Ann Clin Biochem 2014; 51(Pt 2): 189-202.
[19]
Camozzi V, Bonanni G, Frigo A, et al. Effect of a single injection of testosterone enanthate on 17beta estradiol and bone turnover markers in hypogonadal male patients. J Endocrinol Invest 2015; 38(4): 389-97.
[20]
Robinson J, Hodges E, Davison J. Prostate-specific antigen screening: a critical review of current research and guidelines. J Am Assoc Nurse Pract 2014; 26(10): 574-81.
[21]
Kang DY, Li HJ. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis. Medicine 2015; 94(3): e410.
[22]
Shim J, Kim J, Yoon Y, Choi H, Park J, Bae J. Serum Testosterone Levels Are Negatively Correlated with International Prostate Symptom Score and Transitional Prostate Volume. Low Urin Tract Symptoms 2018; 10(2): 143-7.
[23]
Kohn T, Mata D, Ramasamy R, Lipshultz L. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis. Eur Urol 2016; 69(6): 1083-90.
[24]
Karazindiyanoğlu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008; 11(3): 146-9.
[25]
Holmäng S, Mårin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993; 23(2): 99-106.
[26]
Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82(6): 1661-7.
[27]
Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol 2005; 63(3): 280-93.
[28]
Cauley JA. Estrogen and bone health in men and women. Steroids 2015; 99(Pt A): 11-5.
[29]
Boyanov M, Boneva Z, Christov V. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6(1): 1-7.
[30]
Mårin P, Andersson B, Ottosson M, et al. The morphology and metabolism of intraabdominal adipose tissue in men. Metab Clin
Exp 1992; 41(11): 1242-8.
[31]
Zmuda JM, Fahrenbach MC, Younkin BT, et al. The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Metab Clin Exp 1993; 42(4): 446-50.
[32]
Wu Y, Fan Z, Tian Y, Liu S, Liu S. Relation between high density lipoprotein particles concentration and cardiovascular events: a meta-analysis. Lipids in Health and Disease 2018; 17(1): 142.
[33]
Francomano D, Bruzziches R, Barbaro G, Lenzi A, Aversa A. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest 2014; 37(4): 401-11.
[34]
Krysiak R, Gilowski W, Okopień B. The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism. Pharmacol Rep 2016; 68(1): 196-200.